Search hospitals > Florida > Tampa
H. Lee Moffitt Cancer Center & Research Institute
Claim this profileTampa, Florida 33612
Global Leader in Non-Small Cell Lung Cancer
Global Leader in Leukemia
Conducts research for Cancer
Conducts research for Melanoma
Conducts research for Lung Cancer
180 reported clinical trials
22 medical researchers
Summary
H. Lee Moffitt Cancer Center & Research Institute is a medical facility located in Tampa, Florida. This center is recognized for care of Non-Small Cell Lung Cancer, Leukemia, Cancer, Melanoma, Lung Cancer and other specialties. H. Lee Moffitt Cancer Center & Research Institute is involved with conducting 180 clinical trials across 146 conditions. There are 22 research doctors associated with this hospital, such as Ahmad Tarhini, MD, PhD, Rami Komrokji, MD, Joseph Pidala, MD, PhD, and Alberto A Chiappori, MD.Area of expertise
1Non-Small Cell Lung Cancer
Global Leadermetastatic
Stage III
Stage IV
2Leukemia
Global LeaderCD123 positive
T315I positive
Stage I
Top PIs
Ahmad Tarhini, MD, PhDMoffitt Cancer Center4 years of reported clinical research
Studies Melanoma
Studies Cancer
18 reported clinical trials
29 drugs studied
Rami Komrokji, MDMoffitt Cancer Center3 years of reported clinical research
Studies Myelodysplastic Syndrome
Studies Preleukemia
14 reported clinical trials
19 drugs studied
Joseph Pidala, MD, PhDMoffitt Cancer Center2 years of reported clinical research
Studies Graft-versus-Host Disease
Studies Blood Cancers
13 reported clinical trials
26 drugs studied
Alberto A Chiappori, MDMoffitt Cancer Center2 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
12 reported clinical trials
23 drugs studied
Clinical Trials running at H. Lee Moffitt Cancer Center & Research Institute
Breast Cancer
Acute Myeloid Leukemia
Non-Small Cell Lung Cancer
Neuroendocrine Tumors
Leukemia
Myeloid Leukemia
Lung Cancer
Blood Cancers
Blood Diseases
Hematologic and Lymphocytic Disorder
Gedatolisib + Fulvestrant +/- Palbociclib
for Advanced Breast Cancer
This trial is testing a combination of drugs to treat advanced breast cancer that has not responded to other treatments. The drugs work by blocking growth signals, breaking down estrogen receptors, and stopping cell division. Tamoxifen is a commonly used drug that blocks estrogen receptors to treat breast cancer, but resistance to it often develops.
Recruiting2 awards Phase 311 criteria
Combination Therapies
for Breast Cancer
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, four cohorts will be enrolled in parallel in this study: Cohort 1 will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line \[1L\] PD-L1+ cohort). Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line \[2L\] CIT-naive cohort). Cohort 3 will consist of participants with locally-advanced or metastatic HR+, HER2-negative disease with PIK3CA mutation who may or may not have had disease progression during or following previous lines of treatment for metastatic disease (HR+cohort). Cohort 4 will consist of participants with locally-advanced or metastatic HER2+ /HER2-low disease with PIK3CA mutation who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort). In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). In addition, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination (Stage 2), provided Stage 2 is open for enrollment.
Recruiting1 award Phase 1 & 228 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at H. Lee Moffitt Cancer Center & Research Institute?
H. Lee Moffitt Cancer Center & Research Institute is a medical facility located in Tampa, Florida. This center is recognized for care of Non-Small Cell Lung Cancer, Leukemia, Cancer, Melanoma, Lung Cancer and other specialties. H. Lee Moffitt Cancer Center & Research Institute is involved with conducting 180 clinical trials across 146 conditions. There are 22 research doctors associated with this hospital, such as Ahmad Tarhini, MD, PhD, Rami Komrokji, MD, Joseph Pidala, MD, PhD, and Alberto A Chiappori, MD.